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https://doi.org/10.1016/j.immuni.2021.05.010SUMMARYThe kinetics of the immune changes in COVID-19 across severity groups have not been rigorously as-
sessed. Using immunophenotyping, RNA sequencing, and serum cytokine analysis, we analyzed serial
samples from 207 SARS-CoV2-infected individuals with a range of disease severities over 12 weeks
from symptom onset. An early robust bystander CD8+ T cell immune response, without systemic inflamma-
tion, characterized asymptomatic or mild disease. Hospitalized individuals had delayed bystander re-
sponses and systemic inflammation that was already evident near symptom onset, indicating that immu-
nopathology may be inevitable in some individuals. Viral load did not correlate with this early pathological
response but did correlate with subsequent disease severity. Immune recovery is complex, with profound
persistent cellular abnormalities in severe disease correlating with altered inflammatory responses, with
signatures associated with increased oxidative phosphorylation replacing those driven by cytokines tumor
necrosis factor (TNF) and interleukin (IL)-6. These late immunometabolic and immune defects may have
clinical implications.Immunity 54, 1–19,
This is an open access article undJune 8, 2021 Crown Copyright ª 2021 Published by Elsevier Inc. 1
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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The immune pathology associated with COVID-19 is complex
(Wang et al., 2020; Zhou et al., 2020). Most infected individuals
mount a successful anti-viral response, resulting in few, if any,
symptoms. In a minority of patients, there is evidence that
ongoing cytokine production develops, associated with persis-
tent systemic inflammation, end-organ damage, and often death
(Del Valle et al., 2020; Lucas et al., 2020). The relationship be-
tween the initial immune response to SARS-CoV-2, viral clear-
ance, and development of the ongoing inflammatory disease
that drives severe COVID-19 is not clearly established, nor
have the kinetics of the immune changes seen in COVID-19
been fully assessed as disease progresses. Defective immune
recovery might drive ongoing disease and perhaps contribute
to secondary immunodeficiency with an increased risk of subse-
quent infection.
Severe COVID-19 is associated with profound abnormalities in
circulating immune cell subsets. There is a decrease in many pe-
ripheral blood subsets of both CD4+ and CD8+ T cells but an in-
crease in activated and differentiated effector cells (Arunacha-
lam et al., 2020; Hadjadj et al., 2020; Kuri-Cervantes et al.,
2020; Laing et al., 2020; Mann et al., 2020; Mathew et al.,
2020; Su et al., 2020). Cells expressing programmed cell death
protein-1 (PD1) and other inhibitory molecules are increased,
though whether these reflect genuine T cell exhaustion or
changes accompanying T cell activation has not been firmly es-
tablished. There is, nonetheless, evidence of functional impair-
ment in both CD8+ and CD4+ T cells in a number of studies
(Chen and JohnWherry, 2020). Data on T helper (Th) cell subsets
are variable, but there is evidence of increased Th17 cells and
markedly reduced T follicular helper (Tfh) cells (Chen and John
Wherry, 2020; Mathew et al., 2020; Su et al., 2020). There have
been conflicting reports regarding B cell immunity, but increased
circulating plasmablasts (Arunachalam et al., 2020; Hadjadj
et al., 2020; Laing et al., 2020; Mathew et al., 2020) and reduced
germinal center responses (Su et al., 2020) are consistently
observed in severe COVID-19. Innate T cell subsets, including
gamma-delta (gd) T cells and mucosal-associated invariant T
(MAIT) cells, are also reduced, as are non-classical monocytes
and both plasmacytoid and myeloid dendritic cells (pDCs and
mDCs) (Kuri-Cervantes et al., 2020; Laing et al., 2020)
By analyzing transcriptome, serum cytokine, and immunophe-
notyping data of longitudinal samples from COVID-19 patients
with a range of disease severities, for up to 3months from symp-
tom onset, we were able to address two important questions
regarding the immune response to SARS-CoV-2. (1) How does
the very early immune response in patients who cleared the virus
and recovered from disease with few or no symptoms compare
with thosewho progressed to severe inflammatory disease? This
provided insight into the features of the initial immune response
that correlate with severe inflammatory outcomes and whether
systemic inflammation is an early or later development in those
who progress to severe disease. (2) How rapidly do the profound
immune defects that accompany severe COVID-19 recover, and
do the kinetics of recovery relate to ongoing inflammation and
clinical status?
We recruited 207 patients with COVID-19, ranging from
asymptomatic healthcare workers in whom SARS-CoV-2 was2 Immunity 54, 1–19, June 8, 2021detected on routine screening through to patients requiring as-
sisted ventilation, and compared their results to 45 healthy con-
trols. We performed detailed immune phenotyping at multiple
time points up to 90 days from symptom onset, reporting abso-
lute cell counts rather than proportions. All data have beenmade
available at https://www.covid19cellatlas.org/patient/citiid/. We
found that the immune response in patients with progressive
COVID-19 was delayed compared to those with mild disease
and was inflammatory in nature from the outset. Early immune
cellular changes predicted severe disease course, and the vari-
able recovery of these cells over 3 months is associated with
marked changes in the nature of the systemic inflammation
seen in severe COVID-19.
RESULTS
Patient cohorts
SARS-CoV-2 PCR-positive subjects were recruited for this study
between 31st March and 20th July 2020. Those without symp-
toms, or with mild symptoms, were recruited from routine
screening of healthcare workers (HCWs) (Rivett et al., 2020).
COVID-19 patients were recruited at or soon after admission to
Addenbrooke’s or Royal Papworth hospitals.
Study participants were divided into five categories of clinical
severity, used throughout this paper unless otherwise stated
(Figures 1A; Data S1). These were: (A) asymptomatic HCWs;
(B) HCWs who either were still working with mild symptoms
insufficient to meet the criteria for self-isolation (Rivett et al.,
2020) or were symptomatic and self-isolating; (C) patients who
presented to hospital but never required oxygen supplementa-
tion; (D) patients who were admitted to hospital and whose
maximal respiratory support was supplemental oxygen; and (E)
patients who at some point required assisted ventilation. Three
patients who died without admission to intensive care were
also included in this severe group. In addition, 45 healthy con-
trols (HCs), distributed across a range of age and gender, were
recruited.
We analyzed the immune phenotype of 605 blood samples
from 246 participants out to 90 days from the onset of symptoms
(Figure 1A; Tables S1 and S2). As the clinical severity category
increased, patients were more likely to be older and to be male
(Figures 1B and 1C), as expected (Wang et al., 2020). A high-
sensitivity C-reactive protein (CRP) assay demonstrated that
classifying disease severity on the basis of maximal respiratory
support is reflected in the CRP (Figure 1D). Patient courses are
measured in time since symptom onset for groups B through
to E. As they are asymptomatic, those in group A are measured
from the date of their first positive swab; they are therefore likely
to have been sampled later post-infection than patients in
groups B–E, and are therefore not directly comparable to them
in terms of time course. CRP (and, later, other variables) is
compared to the interquartile range of 45 healthy controls.
Nasopharyngeal swabs were assessed for SARS-CoV-2,
allowing inclusion in this study, and were repeated in some
patients. Initial viral titers, reflected by low PCR cycle threshold
(CT) values, were higher in group E. With only occasional excep-
tions, patients in all severity groups had cleared the virus by
24 days after symptom onset (Figures 1D and S1A). Of the six





Figure 1. Cohort characteristics and changes in inflammatory markers over time
(A) Study participant and sample numbers split by severity categories and 12-day time bins post screening (group A) or symptom onset (groups B–E).
(B and C) Distribution of participant age (B) and gender (C) across severity categories.
(D) Boxplots showing CRP (mg/L) and SARS-CoV-2 PCR cycle threshold in 12-day time bins. Gray band, interquartile range of HCs or the SARS-CoV-2 swab
cycle negative threshold (CT > 38).
(E) Heatmap showing log2 fold change in median CRP and serum cytokine and complement measures between COVID-19 cases and HCs, 12-day time bins.
Wilcoxon test FDR adjusted p value: *p < 0.05, **p < 0.005, ***p < 0.0005.
See also Figure S1 and Table S1.
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duction/rejection treatment, one myeloma on B cell depletion
therapy) and one was a peritoneal dialysis patient admitted
with peritonitis.
Wewill outline themajor datasets collected in this study before
integrating them to study early and recovering disease.
Changes in cytokines and complement components
with time and disease severity
Asymptomatic HCWs in group A had no evidence of cytokine or
complement dysregulation, while those with mild symptoms(group B) showed an early, transient increase in C3c and the ter-
minal complement complex (TCC), but not in CRP or cytokine
concentrations (Figures 1E and S1B). Once patients developed
symptoms severe enough to attend hospital (group C or above),
a different picture was apparent. Both interleukin (IL)-6 and tu-
mor necrosis factor (TNF)-a were raised in serum, along with
other cytokines, aswere all complement componentsmeasured.
These abnormalities were maximal at the first bleed and largely
persisted in group E. Abnormal IL-6 and TNF-a persisted in
groups C and D despite clinical improvement (all had been dis-
charged by days 49–60). Interferon-gamma (IFN-g) was brieflyImmunity 54, 1–19, June 8, 2021 3
A
B
Figure 2. Profound immune abnormalities in moderate/severe COVID-19
(A) Boxplots showing absolute counts (cells/mL) for two representative cell populations, by severity groups and 12-day time bins post screening (group A) or
symptom onset (groups B–E). Gray band; interquartile range of HCs.
(B) Heatmap showing the log2 fold change in median absolute cell count (left) or proportion of major subset (right) between COVID-19 cases (samples, n = 362)
and HCs (n = 45), 12-day time bins.
Wilcoxon test FDR adjusted p value: *p < 0.05, **p < 0.005, ***p < 0.0005. Population hierarchy is shown to the left. Population proportions are calculated within
parent populations listed to the right. PB or PBMC, peripheral blood mononuclear cells (flow cytometry); WB, whole blood (CyTOF).
See also Figure S3 and Data S2.
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in group B, while C3a became the dominant complement
component elevated in more severe disease (groups C–E).
IL-6, TNF-a, IL-10, and IL-1b rose in those with more severe
disease (groups C–E), but, in contrast, there was no increase in
inflammatory cytokines in groups A and B, pointing to marked
differences in very early inflammatory responses between
resolving and progressive disease. In addition, the persistence
of cytokine abnormalities even beyond 60 days from symptom
onset could have implications for resolution of clinical disease.4 Immunity 54, 1–19, June 8, 2021Both onset and recovery of immune cellular
abnormalities vary with disease severity
Using standardized flow cytometry panels, we explored the size
of 64 cell populations over time across the five clinical strata.
Trucount analysis enabled calculation of absolute cell numbers.
Cellular changes with time were assessed (examples in Fig-
ure 2A), and outcomes for 30 cell types have been shown relative
to the median for HCs (Figure 2B). CyTOF, which uses whole
blood rather than peripheral blood mononuclear cells (PBMCs),





Figure 3. Whole-blood transcriptomic signatures over time (n = 183)
(A) Heatmap derived from WGCNA, correlating whole-blood co-expression gene modules (colored blocks, y axis) with COVID-19 severity groups (x axis) in
24-day time bins post screening (group A) or symptom onset (groups B–E). Boxes are colored by strength of correlation. For details of annotation (by Enrichr) and
gene content of all modules, see Figure S4 and Table S3. Boxplots show eigenvalues within key transcriptomic modules, according to disease severity and time.
(legend continued on next page)
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(Figure S2; STAR Methods). See Data S2 for details of all cell
types, including data beyond 48 days of symptom onset and
time as a continuous variable.
Few changes in the immune phenotypes were seen in patients
with asymptomatic (A) and very mild (B) disease, but once symp-
toms warranted presentation to hospital, the picture changed.
Widespread immune abnormalities in groups C–E were most
marked at the first bleed (Figure 2B), even when this was within
0–2 days of symptom onset (Data S2). Almost all CD4+ T cells
subsets were reduced, as were many CD8+ T cell subsets and
both naive and memory B cells; in contrast, plasmablast
numbers rose in all groups. Innate lymphoid subsets, including
MAIT cells, various gd T cell subsets, and natural killer (NK) cells,
were also reduced, as were mDCs, and both non-classical and
intermediate monocytes. These changes were correlated with,
and were predictive of, severity, as discussed below.
We also calculated leucocyte number as a proportion of
‘‘parent’’ populations, either of total PBMCs (Figure S3A) or of
major lymphoid compartments (Figures 2B and S3A), to allow
comparison with most published literature (and all single-cell
studies). Considering proportion underestimates COVID-19-
associated pathology, for example, missing the early severity-
correlated reduction in lymphocyte subsets, and the late persis-
tence of low numbers of T cell subsets in severe disease. In
agreement with this, analysis of CyTOF and CITE-seq data,
which also examine cell proportions, did not identify most alter-
ations in cell populations between severity groups that were
observed by flow cytometry (Figures S3B and S3C).
Blood transcriptomic inflammation-related signatures
vary with severity and time
Whole-blood RNAwas isolated, and transcriptomes were gener-
ated by RNA sequencing (RNA-seq) and analyzed (in two time
bins: 0 to 24 days and 25 to 48 days) using PLIER, which per-
forms matrix factorization to identify interpretable latent factors.
The contribution to each latent factor by immune cell subsets
was then calculated (Figures S4A and S4B). These RNA-seq-
derived latent factors were broadly aligned with the pattern
observed in the cell count data (Figure 2B). An exception was
the pronounced neutrophil signature seen early across groups
C to E and persisting at days 25–48 in group E, demonstrating
more pronounced neutrophil dysregulation across severity cate-
gories than suggested by increasing neutrophil number alone.
An erythrocyte gene expression-driven latent factor was also
prominent in group E at late time points, may be associated
with heme metabolism, and is discussed later.
We then used unbiased weighted gene correlation network
analysis (WGCNA) in the whole-blood transcriptome data to
identify modules of co-regulated genes, where each could be(B) Mixed-effects model with quadratic time trend showing the longitudinal expres
Nominal and adjusted p values for the time 3 severity group interaction term sho
(C and D) Mixed-effects model showing longitudinal expression of eigengene
showing changes in SARS-CoV-2 PCR cycle threshold (viral load) by time and s
(E) GSEA enrichment for Hallmark genesets against HC in COVID-19 cases spli
(groups B–E).
FDR adjusted p value is shown by circle diameter, with color representing norm
Table S3.
6 Immunity 54, 1–19, June 8, 2021summarized as an ‘‘eigengene.’’ Prominent modules correlated
with both disease severity and time (Figures 3A, 3B, S4C, and
S4D; Table S3). The module enriched for TNF-a/IL-6 genes cor-
relates well with the cytokine concentrations determined in Fig-
ure 1, rising early in groups C–E and then largely resolving by
25–48 days. A neutrophil activation module was also prominent
early across groups C–E, as was one associated with glycolysis.
Thus, there was clear transcriptional evidence of activation of
broad inflammatory pathways at early time points, and these
largely recovered in most patient groups (with the exception of
group E, in which many patients had persistent disease). In
contrast, an interferon-related module was upregulated in
groups B–E at days 0 to 24 from symptom onset, before
declining (Figures 3A). The relative contributions of type I, II,
and III interferons to this interferon-stimulated gene (ISG)-asso-
ciated module cannot be easily distinguished (Banchereau
et al., 2017), but a more detailed analysis of its kinetics showed
that, while expression peaked at different eigengene values in
each severity group, it then declined in all of them by around
30 days (Figure 3C), coincident with viral clearance and occur-
ring irrespective of clinical and inflammatory state (Figure 3D).
Finally, a supervised gene set enrichment analysis (GSEA) per-
formed using Hallmark gene signatures (Figure 3E) (Liberzon
et al., 2015) showed results largely consistent with the unbiased
approaches just described, including demonstrating a late upre-
gulation of genes associated with reactive oxygen species (ROS)
and oxidative phosphorylation (OXPHOS) discussed below in the
context of immune recovery.
Immune phenotype at presentation correlates with
severity and may predict outcome
To determine whether the immune phenotype at presentation
correlated with, or indeed could predict, subsequent disease
course, we first performed a principal-component analysis us-
ing cell numbers across 24 primary immune cell populations
from the 84 participants with blood draws taken between
0 and 10 days after the development of symptoms. Those in
groups A and B clustered with HCs and away from those in
groups C–E (Figure S5A). Hierarchical clustering of absolute
cell counts identified two clusters (Figure 4A), one almost
entirely comprised of HCWs from groups A and B (cluster 2)
and the other containing all patients who progressed to ventila-
tion and/or death and most who required supplementary oxy-
gen support (cluster 1). Clustering using RNA-seq data ob-
tained from 1–10 days after onset largely recapitulated that
observed using cell number and was driven by ISG-, TNF-a-,
and IL-6-associated gene pathways (Figure S5B). The severe
cluster 1 was associated with increased age, CRP, TNF-a,
and IL-6 (Figure 4B; Data S3A). Early differences between cell
types drove this clustering, irrespective of their differentsion of eigengenes over time by severity. Gray band, interquartile range of HCs.
wn.
capturing interferon-stimulated genes (ISG) (C) and equivalent mixed-model
everity (D). y axis inverted in (D).
t by severity in 24-day time bins post screening (group A) or symptom onset







(legend on next page)
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least-squares discriminant analysis (sPLS-DA) to determine
which cell subsets were most informative for cluster prediction:
clusters 1 and 2 could be discriminated with a minimum classi-
fication error rate of 0.07 ± 0.02 (93% accuracy) based on 13
key cell populations selected by the model (Figures 4C and
S5C–S5E). The area under the receiver operator characteristic
(AUROC) curve for patient cluster classification based on these
13 cell types was 0.98 (98% chance of accurate cluster predic-
tion) (Figure S5F). CRP alone was inferior to the cell types in
classifying patients and did not improve their performance
when added (Figure S5G). These cell types were often the
most profoundly and persistently affected by severe COVID-
19 (particularly MAIT, gd T, Tfh, and CD4+ Temra cells).
The ability to cluster patients and separate those with mild or
no symptoms (groups A and B) from those presenting to hospital
(groups C–E) underlines the profound association of immune
subset abnormalities with disease severity. It does not, however,
predict outcome in a clinically useful way, as such predictions
are only of practical value in thosewho present formedical atten-
tion. We therefore incorporated additional data related to inflam-
mation, including cytokines, age, CRP, and complement compo-
nents; re-clustering with this combined dataset led to a smaller
severity-associated group (Figure 4D). Input from both immune
cell subsets and inflammation-related markers was required for
optimal classification (Figure 4E). When considering only the
subset of patients recruited at hospital presentation (groups
C–E) and bled within 10 days of symptom onset, this clustering
predicted disease progression, as defined by the subsequent
need for increased respiratory support, or death, after blood
sampling (Figure 4F). This analysis requires validation with larger
patient numbers but is comparable to similar observations made
by others (e.g., Laing et al., 2020; Mathew et al., 2020) and indi-
cates that a combination of immune phenotype data and inflam-
matory markers could provide potentially clinically useful predic-
tion of disease progression.
Early immune responses correlate with COVID-19
severity
HCWs in groups A and B did not progress to severe COVID-19
disease and also clustered apart from those with more severe
disease when using either early immune cell counts or transcrip-
tome data (Figures 4A and S5B). Therefore, we compared theFigure 4. Multivariate analysis of immune-cell populations in early dise
(A) Unsupervised clustering of absolute cell counts across 24 cell populations (n
screening (group A) or symptom onset (groups B–E). Cases group into two cluster
Ward D hierarchical clustering.
(B) Boxplots comparing age and inflammatory characteristics of individuals in cl
(C) Thirteen cell types selected by sPLS-DA as most informative in predictive mod
weights of selected features (ranked from most to least informative in cluster pre
(D) Addition of age, CRP, serum cytokine, and complement measures to unsupe
patients by severity (cluster 1, orange, n = 17. cluster 2, purple, n = 38).
(E) AUROC curve showing sensitivity and specificity of severity group prediction
CRP, or serum measures alone compared to all available measures.
(F) Kaplan-Meier plot of escalation-free survival in individuals within severity cluste
respiratory support or death.
p value for the chi-square test of the difference between cluster 1 (n = 17) and hos
patients in each group from days 0 to 30 post symptom onset.
See also Figure S5 and Data S3.
8 Immunity 54, 1–19, June 8, 2021early features of immune responses in groups A and B to those
in patients with more severe COVID-19, binned in 7-day intervals
to provide finer definition, to seek early immune and inflamma-
tory correlates of disease severity (Figure 5A).
A number of key features emerged. First, there was no evi-
dence of systemic inflammation in groups A and B. CRP was
normal (Figure 5A), cytokines were not raised (Figure 1E), and
there was no RNA evidence of systemic inflammatory gene-
related signatures (Figures 3A and 3B). Exceptions were tran-
sient increases in C3c and TCC. Most cell types that were pro-
foundly reduced in groups C–E were normal in A and B (Figures
2 and S3), but some showed mild reductions in group B; pDCs
and memory B cells have been shown as examples (Figures
5A–5C, S6A, and S6B). The fall in pDCs was modest and brief
compared to severe disease and was consistent with tissue
localization and local interferon production to support the anti-
viral response (Cella et al., 1999).
In group B, cytotoxic CD8+ T cells rose earlier than in groups
C–E, apparent by day 7 and peaking up to 2 weeks after symp-
tom onset, in contrast to the later andmore sustained rise seen in
severe COVID-19 (Figures 5A, 5B, and S6A). Early enrichment of
a CD8+ cytotoxic RNA signature was also seen in group B
compared to C to E (Figure S6C). Consistent with these findings,
spontaneous generation of IFN-g by T cells was more pro-
nounced in group B samples taken 2 weeks post symptom onset
(Figure 5D).
Antigen-specific CD8+ T cell responses were determined after
stimulation with anti-SARS-CoV-2 peptides and subtraction of
background spontaneous IFN-g-producing T cells. They were
similar in all severity groups early (Figures 5D and S6D) and so
were not responsible for the increased effector CD8+ T cells
seen in mild disease, suggesting instead a role for ‘‘bystander’’
activation. Such bystander-activated cells are important in early
anti-viral defense (Maurice et al., 2021) and characteristically ex-
press NKG2D, involved in the killing of infected cells, and both
IL-7 receptor (IL7R) and CD8, which are downregulated in a
T cell receptor (TCR)-dependent fashion (Kaech et al., 2003;
Slifka and Whitton, 2000). CITE-seq protein expression analysis
of activated CD8+ T cells demonstrated an increase in surface
NKG2D, IL7R, and CD8 in group B compared to more severe
groups (Figure 5E), observations confirmed by RNA analysis
(Figure 5E). Bystander CD8+ T cells expressing CXCR3 rapidly
home to sites of inflammation (Maurice et al., 2021), consistentase correlates with clinical outcome
ormalized to the median of HCs) for COVID-19 samples taken %10 days from
s (cluster 1, orange, n = 46; cluster 2, purple, n = 38) by Euclidean distance and
usters 1 and 2 at the time of sampling.
els discriminating patients in clusters 1 and 2. Bars indicate loading coefficient
diction, from bottom to top).
rvised clustering of cellular data in (A) results in tighter grouping of COVID-19
(derived from clustering in D), based on absolute counts of 24 key cell types,
r 1 or cluster 2 split by hospitalization status. Escalation defined as a step up in










Figure 5. Early immune changes associated with mild or severe disease outcome
(A) Heatmap showing the log2 fold change inmedian absolute cell counts, CRP or complement measures betweenCOVID-19 cases andHCs by severity and in 7-
day time bins post screening (group A) or symptom onset (groups B–E). Wilcoxon test FDR adjusted p value: *p < 0.05, **p < 0.005, ***p < 0.0005.
(B and C) Mixed-effect model with quadratic time trend showing cellular trajectories over time in sample groups B, D, and E in non-naive HLA-DR+CD38+ CD8
T cells (B) or plasmablasts (C) (cells/mL) from weeks 1–3 post symptom onset (samples, n = 207).
(legend continued on next page)
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ure 5E). Transcriptional signature-derived bystander-activated
CD8+ T cells were enriched in patients with mild disease, while
those from TCR-activated cells were associated with severe
COVID-19 (Figure 5F), again consistent with widespread early
bystander activation in the CD8+ T cell population in patients
destined to have good disease outcomes.
An early increase in plasmablasts was seen in groups A and B,
occurring up to a week before a larger rise in more severe dis-
ease (Figures 5C and S6B). We therefore measured total immu-
noglobulin concentrations and anti-spike IgG and anti-SARS-
CoV-2 neutralising antibody titers (Figures 5G, 5H, S6E, and
S6F). Group B patients maintained their serum IgM concentra-
tions, which fell rapidly in those with more severe disease (Fig-
ure S6G), and their titers of anti-spike IgG and early neutralisation
responses were comparable to patients progressing to more se-
vere COVID-19 (Figures 5G and 5H). This suggests that the B cell
difference between patients with mild and more severe disease
might lie in more robust non-antigen-specific B cell activation,
perhaps impacting via ‘‘natural’’ antibody and/or non-antibody-
dependent mechanisms.
Virus at first swab, as assessed by PCRCT value, was compa-
rable in groups B, C, and D (and the lower titer in group A sam-
ples was not comparable as they will have been taken later after
infection, as described above). Initial viral titer was therefore not
associated with an increased risk of hospital admission (being
similar in groupsB,C, andD) butwas higher in groupE (Figure 5I).
These viral titers were reflected in interferon-related transcription
signatures, which are prominent in groups B–E (Figures 3A, 3C,
and S6H). Despite the fact that high IFN signatures correlated
with severe disease, they were not necessarily driving that
severity. The fact that the subgroup with the highest IFN within
group E do best (Figure S6I) suggests that the inflammatory
pathways that create severe disease are distinct from IFN (which
is also consistent with comparable kinetics of reduction of IFN
signature regardless of severity; Figure 3C) and that a robust
IFN responsemay be beneficial in this context, though this needs
confirmation in a larger dataset.
Taken together, these data suggest that an early adaptive im-
mune response is prominent in individuals who are asymptom-
atic or have mild disease, characterized by a rapid production
of activated bystander CD8+ T cells, plasmablasts, and likely
pDC tissue localization before antigen-specific responses
become apparent. This appeared a more important correlate
of severity than viral titer, which only became relevant in those
progressing to ventilation or death (Figure 5J).(D) Number of CD3+ T cells secreting IFN-g spontaneously or following SARS-CoV
(n = 25), 1 or 2 weeks post symptom onset. Kruskal-Wallis test p values: *p < 0.0
(E) Log2 fold change (FC) in expression of CD8
+ T cell transcripts reflecting T cell ac
seq data from non-naive CD8+ T cells from patients in groups A and B (n = 5) an
(F) Normalized gene set enrichment score for gene sets associated with TCR-de
non-naive CD8+ T cells from patients in groups A and B versus C, D, and E. FDR
(G) Area under the curve for SARS-CoV-2 spike-specific IgG titers at 1, 2, and 5we
E are combined to increase statistical power, Kruskal-Wallis test p values annota
(H) SARS-CoV-2 antibody titers achieving 50% neutralization (NT50) in patients fro
no detectable neutralizing activity at the lowest dilution (dotted line) are plotted a
(I) Boxplots showing SARS-Cov-2 viral load, taken as first positive swab PCR CT
(J) Schematic summarizing variation in immune features of SARS-CoV-2 infectio
See also Figure S6.
10 Immunity 54, 1–19, June 8, 2021In those with more severe disease (groups C–E), evidence of
systemic inflammation was present from the first blood test
(Figure 5). If we focused on the 16 patients in groups C–E
sampled between 2 days before and 4 days after symptom
onset, 15 had a CRP >10 mg/L and/or neutrophil activation
eigengene >0. All five patients sampled between 2 days before
and 2 days after symptom onset met these criteria. In contrast,
this was not seen in group A or B despite the fact that they
mounted a more prominent early cellular response. It was not
clear whether inflammation seen in C–E was causally related to
the poor early cellular response seen in these patients. Such
inflammation clearly did not, however, develop later from the pro-
gression of a non-inflammatory immune response or as a result of
failure to clear virus and suggested that the inflammatory die is
cast by the time symptoms appear; thus, strategies to prevent
it and reduce its clinical impact would need to be established
very early (Figure 5J).
Distinct patterns of immune recovery in COVID-19
In contrast to groups A and B, cellular changes in groups C–E
were profound and usually most prominent at the first bleed (Fig-
ure 2), so determination of change in immune cell subsets over
timewas likely to bemost informative in these groups. Therefore,
we explored cell kinetics in groups C–E, assigning patients to
two categories based on whether their CRP concentrations re-
mained elevated above 10 mg/L (‘‘persisting CRP’’) or fell below
10 mg/L (‘‘resolving CRP’’) by their final bleed within 3 months
post symptom onset (Figure 6A). The latter group included
both individuals with early high CRP that then fell, together
with those for which CRP remained low (10 mg/L) throughout.
Changes in CRP over time differed between these two groups
when assessed using a mixed-effects model, with time modeled
as a continuous variable (Figure 6B).
To compare cellular changes over time between persisting
and resolving CRP patient groups, a ‘‘rate of change’’ for each
cell population was calculated over 60 days post symptom
onset. In brief, this rate captured both the initial deviation in
cell counts from normal within a window of 0–12 days and the
time taken for cells counts to stabilize within a normal range if
cellular recovery did occur (see STAR Methods). Five predomi-
nant trajectories were observed; populations that did not deviate
from heathy numbers over the duration of study (e.g., NKT cells),
those that increased progressively from normal over time (e.g.,
effector CD8+ T cells), those that fell progressively from normal
over time (e.g., transitional B cells), those that trended toward re-
covery after an initial rise in numbers (plasmablasts), and those-2 antigen stimulation in samples from groups B (n = 22) and D and E combined
5.
tivation and surface protein expression (detected by antibody staining) in CITE-
d C, D, and E combined (n = 13), relative to HCs (n = 11).
pendent and bystander T cell activation in single-cell transcriptomic data from
adjusted p value shown by circle diameter.
eks post screening (group A) or symptom onset (groups B–E). Groups C, D, and
ted as in (A).
m groups B–E in the first 2 weeks post symptom onset (n = 102). Samples with
t an arbitrary NT50 of 1. p value and Pearson’s correlation shown.
, in severity groups. Wilcoxon test p values annotated as in (A).




Figure 6. Cellular and transcriptional trajectories in persisting and resolving disease (n = 263)
(A) CRP (mg/L) from groups C, D, and E grouped by persisting and resolving CRP.
(B) Mixed-effect model with quadratic time trend showing log2(CRP) trajectories in both patient groups, and the likelihood-ratio test p value for the time3 group
interaction term. Gray band, interquartile range in HCs.
(C) Heatmap showing the log2 fold change inmedian absolute cell count between COVID-19 cases in groups C, D, and E, split according to persisting or resolving
CRP, and HCs. 12-day time bins. Wilcoxon test FDR adjusted p value: *p < 0.05, **p < 0.005, ***p < 0.0005. Rate of cell number changes shown by lollipop plot;
(legend continued on next page)
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naive CD4+ T cells) (Figure 6C).
The absolute number ofmost cell populations fell precipitously
early and then showed variable recovery. For descriptive pur-
poses, these were arranged into a group of cell subtypes that
failed to recover, or recovered, in the persisting CRP group (Fig-
ure 6C, quadrants I and III, respectively) and their equivalents in
the resolving CRP group (Figure 6C, quadrants II and IV, respec-
tively). Notably, a few populations remained abnormal in both
persisting and resolving CRP groups out to 60 days post symp-
tom onset, including pDCs, Tfh,MAIT, and Vg9Vd2 (hi) gd T cells.
All other populations showing an early drop in counts (with the
exception of naive CD8+ T cells) recovered in those with
resolving CRP (II and IV) and at rates more rapid than seen in
those with persisting high CRP. In the persisting CRP group, a
number of cell types remained markedly abnormal (including
memory B cells and various CD4+ T cell subsets: quadrant I),
whereas a second group of cell types recovered despite persist-
ing inflammation (including NK cells and some CD8+ T cell sub-
sets: quadrant III).
We then explored the relationship between cell recovery and
the inflammatory response. It might be expected that where
CRP remained persistently elevated, immune defects might
persist, if these defects were secondary to the inflammatory
state. Consistent with this, the cohort with persistently raised
CRPalso has raisedTNF-a and IL-6 protein (Figure 1D). Likewise,
transcriptional signatures of TNF-a/IL-6 and neutrophil activation
were increased in severe disease (Figure 3), particularly in the
persistent CRP group (Figure 6D). This ongoing inflammation
may contribute to the sustained reduction in cell numbers at
late times seen in quadrant I, together with persistently raised
HLA-DR+/CD38+ effector T cells and plasmablasts (Figure 6C).
Therefore, it was also not unexpected that most cell types
reduced in acute disease recover over a few weeks as the CRP
falls, as was seen for most cells in quadrants II and IV (Figure 6C).
More intriguing were the cells that recovered rapidly in the face
of ongoing inflammation (quadrant III). While the reasons for this
are likely to differ between cell types and to be multifactorial,
these cell reductions might be driven in part by the viral infection
per se and/or virus-induced interferon. It was notable that, after
initially rising, IFN-g (Figures 1E and S1B) and ISG signatures fell
to normal values independent of both disease severity group
(Figure 3C) and CRP (Figure 6D) but correlated with declining vi-
rus titer (Figures 3D and S4E). Thus, cell types known to leave the
circulation due to interferon stimulation (Kamphuis et al., 2006),
such as T and NK cells (Hirsch and Johnson, 1986; Zafranskaya
et al., 2007), may recover as viral infection is controlled and inter-
feron-dependent inflammation falls, independent of ongoing
CRP-associated inflammation.
Finally, a small number of cell types remained statistically
abnormal after 60 days, even in the resolving CRP group.
Thus, effector CD4+ and CD8+ T cells and plasmablasts re-
mained elevated, and pDCs, Tfh, MAIT, and Vg9Vd2-expressing
gd T cells remained reduced (Figure 6C) and were among thosefaster rate of recovery, or deviation from normal, is indicated by increasing stem len
HCs at 0–12 days; black outline indicates failure to recover to HC numbers withi
(D) Mixed-effect models showing longitudinal trajectories of gene module eigen
metabolism, and oxidative phosphorylation in CRP groups, p values reported as
12 Immunity 54, 1–19, June 8, 2021cellsmost predictive of poor prognosis (Figure 4C). These abnor-
malities persist despite resolution not only of CRP but of neutro-
phil degranulation, TNF-a/IL-6, and glycolysis-related signatures
(e.g., Figures 1D and 6D). Possible mechanisms behind these
sustained abnormalities are discussed below.
The late appearance of OXPHOS and ROS pathways
correlates with differential immune recovery
In late, severe COVID-19, whole-blood transcriptome analysis
showed prominent inflammation-related signatures that were
distinct from those seen early in disease. These signatures
were related to OXPHOS, ROS, and heme metabolism. These
were demonstrated in an unbiased fashion using WGCNA,
where modules characterized by OXPHOS and heme meta-
bolism were prominent at days 25 to 48 post symptoms, with
OXPHOS most prominent in group E and heme metabolism in
C-E (Figures 3B and 3C). Enrichment of Hallmark signatures
confirmed the association of OXPHOS and heme metabolism
in groups C–E and also found association of a ROS signature
(Figures 3E and 7A). Consistent with this, the expression of the
genes driving the enrichment of each signature was upregulated
in the three most severe clinical groups (Figure 7B; Table S3).
The late rise in these three correlated signatures occurred irre-
spective of persisting or resolving CRP-associated inflammation
(Figure 6D) and appeared independent of specific cell population
recovery (Figure S7A).
We then correlated cellular and transcript signature changes in
COVID-19. In the first 24 days after symptom onset, there was a
strong association between TNF-a/IL-6, neutrophil degranula-
tion, and interferon signatures with most cell subsets reduced
in severe disease (Figure S7B). Later, between 24 and 48 days
after symptom onset, these associations changed (Figures 7C
and S7C). While TNF-a/IL-6 and neutrophil degranulation signa-
tures were still associated with many cell subsets that continue
to be reduced, the interferon signature was no longer a signifi-
cant player. The persistent increase seen in activated effector
CD4+ and CD8+ T cells and plasmablasts was now particularly
associated with the OXPHOS signature, which, having become
more prominent later in disease (Figure 3B), had a much more
restricted and specific association with immune dysfunction
than other inflammatory signatures.
It was thus clear that, for some cell types, the association be-
tween their number and the inflammatory milieu changed over
time but, for others, was more consistent. It was the inflamma-
tory signatures that appeared late in disease, in particular
OXPHOS, that were specifically associated with persistent
derangement of cell types of potential pathological importance,
such as increased HLA-DR+CD38+ T cells and plasmablasts and
reduced pDCs (Figure 7D).
DISCUSSION
In asymptomatic or mildly symptomatic, non-progressive SARS-
CoV-2 infection (groups A and B), there was evidence of an earlygth. Points are colored by log2 fold change inmedian absolute cell counts from
n 60 days (defined in STAR Methods).





Figure 7. Altered transcriptional changes in prolonged disease (n = 183)
(A) Enrichment score for Hallmark genesets capturing heme metabolism, OXPHOS- and ROS-related genes (by GSEA) in groups A–E in samples taken
25–48 days post screening (group A) or symptom onset (groups B–E).
(B) Heatmap showing relative expression of the intersection of GSEA leading edge genes from groups C, D, and E, across severity groups in samples taken
25–48 days post screening (group A) or symptom onset (groups B–E).
(C) Heatmap showing correlation between transcriptional eigengenes and absolute cell counts, at 25–48 days post symptom onset. Boxes are colored by
strength of correlation, Pearson correlation p values: *p < 0.05, **p < 0.01, ***p < 0.001.
(D) Schematic representation of the trajectory of immunological changes in SARS-CoV-2 infection over time in patients with persisting or resolving systemic
inflammation.
See also Figure S7.
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CD8+HLA-DR+CD38+ activated T cells expanded earlier and in
higher numbers than in more severe COVID-19 groups, most
notably in the first week after symptom onset. Both of these
cell populations then contracted in A and B, as they continued
to rise in groups C–E. Despite this, and a prominent early inter-
feron transcription signature, both the antibody and T cell
SARS-CoV-2-specific immune responses were comparable be-
tween early mild and severe disease. This suggested that the
increased plasmablasts and effector CD8+ T cells could reflect
an enhanced bystander response in mild disease, something
then supported by single-cell CITE-seq analysis.Bystander CD8+ T cell activation was first described in the
context of lymphocytic choriomeningitis virus (LCMV) infection
in mice (Tough et al., 1996). It involves activation of memory
CD8+ T cells independent of TCR stimulation (whether by the
initiating or cross-reactive antigen) (Maurice et al., 2021). It is
driven by type I IFN in many inflammatory contexts—in partic-
ular, viral infection. Bystander CD8+ T cells are activated well
before the antigen-specific response is seen, being detectable
within a day of viral infection and often peaking within a week
(Berg et al., 2003). Bystander cells can migrate to infected or-
gans using CXCR3 and kill virally infected cells through
NKG2D- and granzyme-B-dependent mechanisms (MauriceImmunity 54, 1–19, June 8, 2021 13
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the early defense against viral infections, in part by direct anti-
viral effects and in part by producing IFN-g and other cytokines
that then activate antigen-presenting cells (Soudja et al., 2014)
and control the memory/effector balance of subsequent anti-
gen-specific responses (Krummel et al., 2018). Similar, though
less well defined, bystander phenomena occur in CD4+, MAIT,
and gd T cell responses (Holzapfel et al., 2014; Ribeiro et al.,
2015; Ussher et al., 2018). The early and pronounced production
of bystander-activated CD8+ T cells in patients groups A and B
could be directly related to disease resolution and prevention
of progression to more severe disease, a process likely to begin
before symptom onset. Understanding the factors that impede
this early bystander response could be important for developing
strategies to prevent severe disease.
In contrast, persistent bystander CD8+ T cell activation has
been associated with inflammatory pathology in the context of
both chronic infection and autoimmunity. NKG2D-dependent
killing of non-virally infected hepatocytes in hepatitis A exacer-
bates liver damage (Kim et al., 2018) and may also play a role
in inflammatory lung disease (Borchers et al., 2009), and there
is evidence that NKG2D ligands are expressed in the lungs in
COVID-19 (Wauters et al., 2021), so it could be that a late and
persistent expansion of bystander-activated effector T cells in
severe COVID-19 could be a driver of lung pathology. The
well-documented links between bystander CD8+ T cell activation
and autoimmunity (Groh et al., 2003; Meresse et al., 2004) also
raise the possibility that they may play a role in the autoimmune
manifestations observed in COVID-19.
The early increase in circulating plasmablasts seen in mild
COVID-19 is likely to be comprised of SARS-CoV-2-specific
cells, perhaps to an extent not yet fully reflected in serum anti-
bodies, together with non-SARS-CoV-2-specific bystander-acti-
vated cells. Bystander B cell activation is known to involve mem-
ory (Horns et al., 2020) as well as innate-like B cells (including B1
cells in themouse andmarginal zone cells in bothmouse and hu-
man). Their function is not fully defined but includes an increase
in production of ‘‘natural antibodies’’ (Antin et al., 1986) along-
side non-antibody-associated functions, which may include
antigen transport to secondary lymphoid organs, antigen pre-
sentation to T cells, cytokine production, and immune regulation.
These bystander B cell functions are known to play a role in early
defense against bacterial infection (Boes et al., 1998; Haas et al.,
2005; Ochsenbein et al., 1999) and may be involved in autoim-
munity (Espéli et al., 2019; Sanderson et al., 2017). Their role in
viral infection is less clear, but it may be that early bystander B
cell activation helps determine the outcome of COVID-19 in a
manner analogous to the role proposed for bystander CD8+
T cells. A closer investigation of the early B cell response in
COVID-19 will be required to confirm this.
At the same time as this pronounced early immune response is
seen in groups A and B, there is no evidence of systemic inflam-
mation, apart from early, transient complement activation. CRP,
circulating TNF-a and IL-6, and transcriptional signatures of a
number of inflammatory pathways are not raised in groups A
and B but are already prominent in groups C–E. The severe
and widespread leucocyte subset depletion seen at the initial
bleed in the more severe COVID-19 patient groups C–E, and
observed by many others (Carissimo et al., 2020; Laing et al.,14 Immunity 54, 1–19, June 8, 20212020; Mathew et al., 2020; Su et al., 2020), is not apparent in
those with asymptomatic or mildly symptomatic disease, sug-
gesting that this, too, is a feature of a pathological immune
response. Immune cell subset numbers correlated strongly
with severe and progressive disease. Coupled with evidence of
early systemic inflammation in severity groups C–E, our findings
suggest that the immune pathology associated with severe
COVID-19 either is established immediately post infection or, if
there is a transition point from an effective to a pathological
response, is likely to occur before the time of symptom onset.
This finding may have major implications as to how disease
needs to be managed, because intervention to prevent immune
pathology would need to be targeted very early in the disease
course and perhaps pre-emptively in high-risk groups screened
and diagnosed before symptoms develop.
The reason for the failure to mount a robust early B and T cell
response in the context of severe COVID-19 was likely to be
multifactorial. There was no evidence for a relationship with viral
load and progression to inflammatory disease, as initial viral ti-
ters were comparable between groups B, C, and D. Once inflam-
matory disease is established, however, viral titer may be asso-
ciated with subsequent outcome, as increased viral titer was
seen in group E, consistent with reports that high initial viral titer
might be associated with mortality (Pujadas et al., 2020). Genetic
association studies in severe COVID-19 point to genes that are
implicated in driving antiviral responses. The most prominent
are associations with genes involved in the type I interferon
pathway (Pairo-Castineira et al., 2020; Zhang et al., 2020),
known to be the key driver of bystander T cell activation (Maurice
et al., 2021). Increasing age and comorbidity such as diabetes
and chronic inflammatory disease are known to suppress early
CD8+ T and B cell responses (Shen-Orr et al., 2016; Weiskopf
et al., 2009). An in-depth understanding of these risk factors
may instruct strategies to assess risk of progression before in-
flammatory responses become self-sustained.
While clear distinctions in immune responsiveness were
apparent between groups A and B versus groups C, D, and E,
differences between the more severe groups themselves were
less obvious. Those with symptomatic disease warranting
admission to hospital clustered together using the size of just
13 key cell populations: these clusters correlated strongly with
clinical severity, and immune cell subset numbers together
with inflammatory mediator concentrations provided prediction
of subsequent progression, as well as COVID-19-associated
death. Similar observations have been made by others (Chen
and John Wherry, 2020). Predicting progression after presenta-
tion to hospital with moderate/severe disease could be of limited
clinical use, and it would be of more benefit to predict progres-
sion in cases with milder COVID-19, but this may not be possible
in practice, given that inflammatory immunopathology is likely to
be present at symptom onset. A study to address this issue
would need to be conducted in particularly high-risk patient
groups to ensure an adequate event rate andwould require diag-
nosis through asymptomatic screening to detect changes before
symptoms develop.
We can find no equivalent studies in other severe infections
that explore the kinetics of the cellular immune response across
this range of time and clinical severity. Nonetheless, many of the
changes seen in response to SARS-CoV-2 have been reported in
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blood pDC and T cells has been shown in respiratory syncytial
virus (RSV) (Russell et al., 2017) and influenza A (Fox et al.,
2012; Lichtner et al., 2011), for example. NK cells in the blood
also fall in influenza, probably as a result of migration to the
lungs. Finally, plasmablast expansion has also been seen,
particularly in dengue fever (Wrammert et al., 2012). The nature
of these studies makes a direct comparison with the situation
in SARS-CoV-2 difficult, but it would seem likely that many
immunological changes seen in COVID-19 mirror those seen in
responses to other infections, though, in general, the cellular
changes we observe appear to be more profound, peak earlier
in disease course, and are more persistent in COVID-19 than in
studies performed in other infectious contexts.
The recovery of the profound immune dysregulation seen in
severe COVID-19 is potentially of major clinical relevance, as
such recovery may be required for the resolution of inflammatory
disease or to prevent secondary infection or SARS-CoV-2 rein-
fection. We found that immune cell abnormalities often persist
for weeks to months after SARS-CoV-2 infection, and different
cell populations exhibited quite different patterns of resolution.
Some recovered as systemic inflammation resolved, others did
not, and a third group resolved even in the face of persistent sys-
temic inflammation. Understanding the inflammatory drivers or
associations of this differential recovery could provide insight
into the immune pathology of COVID-19 and potentially of other
infections. To begin to explore this, we correlated immune
changes with measurements of systemic inflammation
throughout the disease course. Patients with severe COVID are
characterized by high CRP, and this correlates with evidence
of TNF-a- and IL-6-driven processes at both the protein and
transcriptome expression levels, as well as with both neutrophil
activation and glycolytic metabolism. The fact that many cellular
abnormalities persisted while these biologic processes were
apparent, while others appeared to resolve alongside them, sug-
gests that the nature of systemic inflammation is important in
driving different aspects of immune pathology.
Finally, some cell populations remained markedly abnormal or
showed a limited recovery, even once CRP-associated inflam-
mation had resolved and indeed after patients had been dis-
charged from hospital. These persistent changes may reflect a
slow intrinsic regenerative capacity of the cell type concerned,
but in other situations, such as the continued elevation of effector
T and B cells, it is tempting to speculate that there is ongoing
abnormal signaling driving such changes. For that reason, we
explored late changes that are seen in the inflammatory
response in COVID-19. Transcriptional signatures associated
with OXPHOS-, ROS-, and heme-related metabolic pathways
arose late in those with severe COVID-19 but were not prominent
in early disease. Activation of immune cells results in metabolic
reprogramming that supports cell growth, proliferation, and
differentiation. Disruption of metabolic pathways can, through
many machanisms, result in immune dysfunction (Bantug
et al., 2018). It is unlikely that the metabolic signatures observed
here simply reflect heightened bioenergetic requirements of acti-
vated immune cells, as one would expect similar requirements to
be also present early in disease. OXPHOS can drive inflamma-
tion (Mills et al., 2017), and we note that COVID-19 patients
treated with metformin, which inhibits complex I of the respira-tory chain, had lower amounts of circulating inflammatory cyto-
kines (Cheng et al., 2020). The ROS transcriptional signature
may reflect more abundant production of ROS, inevitably
accompanying increased OXPHOS. Alternatively, it may reflect
specific mitochondrial pathology and thus contribute to immune
cell dysfunction (Nathan and Cunningham-Bussel, 2013). Mito-
chondria are also critically involved in heme biosynthesis.
Heme serves as a prosthetic group for haemoglobin as well as
many other proteins, including several that constitute the respi-
ratory chain of mitochondria. While free heme can act as a dam-
age-associated molecular pattern and promote ROS formation,
the role of heme biosynthesis versus catabolism in balancing
cellular sensitivity to oxidants is complex and context dependent
(Prestes et al., 2020). Here, given correlated regulation of heme
and OXPHOS pathways in the clinical groups C–E, activity of
these modules may be interrelated and possibly together reflect
dysfunctional mitochondria. How heme and OXPHOS transcrip-
tional programmes are linked on a molecular level cannot be in-
ferred from our data. Erythroid cell activation has recently been
detected in severe COVID-19 (Bernardes et al., 2020) and could
also contribute to a heme transcriptional signature. However, the
increase in heme metabolism in our cohort correlates strongly
with falling haemoglobin, and reticulocytes in patients in groups
C, D, and E are low, suggesting suppression rather than activa-
tion of erythropoiesis. Understanding the mechanism linking
metabolic dysregulation to persistent immune pathology in
COVID-19 will require further study over longer disease courses.
Limitation of study
Many of the abnormalities we have observed in COVID-19 might
also be features of other severe viral infections. To identify which
are COVID specific will require a comparison with an appropriate
disease control group. Sample size is critical when studying
heterogeneous disease, and severe COVID-19 falls into this
category. While the cohorts described here are comparable in
size with other large detailed immunophenotyping studies, larger
ones would nonetheless increase our power. In particular, valida-
tion of the prognosis predictionmodels described here is required
in large independent cohorts. Very early features of the immune
response are associated with disease outcome; exploring these
during the period between infection and symptom onset will be
important for understanding disease progression but presents
major practical difficulties. Continued follow-up of patients will
be needed to determine the persistence of abnormalities still
observed at late timepoints. Finally, because our patientswere re-
cruited during the first pandemic wave, a follow-up study exam-
ining the immune response to new SARS-CoV-2 strains with
different virulence could be informative.
STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
d KEY RESOURCES TABLE
d RESOURCE AVAILABILITYB Lead contact
B Materials availability
B Data and code availabilityImmunity 54, 1–19, June 8, 2021 15
ll
OPEN ACCESS Article
Please cite this article in press as: Bergamaschi et al., Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune





B Clinical data collection







B IFN-m FLUOROSPOT assays
B SARS-CoV-2 serology
B SARS-CoV-2 neutralisation assay
B Whole blood bulk RNA-Seq
B Single cell RNA-seq
d QUANTIFICATION AND STATISTICAL ANALYSIS
SUPPLEMENTAL INFORMATION
Supplemental information can be found online at https://doi.org/10.1016/j.
immuni.2021.05.010.
CONSORTIA
The members of the Cambridge Institute of Therapeutic Immunology and In-
fectious Disease-National Institute of Health Research (CITIID-NIHR) COVID
BioResource Collaboration are John Allison, Ali Ansaripour, Stephen Baker,
Laura Bergamaschi, Ariana Betancourt, Sze-How Bong, Georgie Bower,
John R. Bradley, Ashlea Bucke, Ben Bullman, Katherine Bunclark, Helen
Butcher, Jo Calder, Laura Canna, Daniela Caputo, Debbie Clapham-Riley,
Chiara Cossetti, Jerome D. Coudert, Eckart M.D.D. De Bie, Aloka De Sa, Ele-
anor Dewhurst, Giovanni di Stefano, Jason Domingo, Gordon Dougan,
Benjamin J. Dunmore, Anne Elmer, Madeline Epping, Codie Fahey, Stuart
Fawke, Stewart Fuller, Anita Furlong, Nick Gleadall, Ian G Goodfellow, Stefan
Gr€af, Barbara Graves, Jennifer Gray, RichardGrenfell, Ravindra K. Gupta, Julie
Harris, Christoph Hess, Sarah Hewitt, Andrew Hinch, Josh Hodgson, Elaine
Holmes, Christopher Huang, Oisı́n Huhn, Kelvin Hunter, Tasmin Ivers, Sarah
Jackson, Isobel Jarvis, Emma Jones, Jane Kennet, Sherly Jose, Masa Josi-
povic, Mary Kasanicki, Nathalie Kingston,Jenny Kourampa, Elisa Laurenti,
Ekaterina Legchenko, Paul J. Lehner, Emma Le Gresley, Daniel Lewis, Rachel
Linger, Paul A. Lyons, Michael Mackay, John C.Marioni, JimmyMarsden, Jen-
nifer Martin, Cecilia Matara, Nicholas J. Matheson, AnneMeadows, SarahMe-
loy, Nicole Mende, Federica Mescia, Alice Michael, Rachel Michel,Lucy
Mwaura, Francesca Muldoon, Francesca Nice, Criona O’Brien, Ciara O’Don-
nell, Georgina Okecha, Ommar Omarjee, Nigel Ovington, Willem H. Owehand,
Sofia Papadia, Caroline Patterson, Marianne Perera, Isabel Phelan, Linda
Pointon, Petra Polgarova, Gary Polwarth, Nicole Pond, Jane Price, Cherry
Publico, Rebecca Rastall, Carla Ribeiro, Nathan Richoz, Veronika Romashova,
Sabrina Rossi, Jane Rowlands, Valentina Ruffolo, Caroline Saunders, Natalia
Savinykh Yarkoni, Rahul Sharma, Joy Shih, Mayurun Selvan, Kenneth G.C.
Smith, Sarah Spencer, Luca Stefanucci, Hannah Stark, Jonathan Stephens,
Kathleen E Stirrups, Mateusz Strezlecki, Charlotte Summers, Rachel Sutcliffe,
James E.D. Thaventhiran,Tobias Tilly, Zhen Tong, Hugo Tordesillas, Carmen
Treacy, Mark Toshner, Paul Townsend, Lori Turner, Neil Walker, Jennifer
Webster, Michael P. Weekes, Nicola K. Wilson, Jennifer Wood, Marta Wylot,
and Cissy Yong.
ACKNOWLEDGMENTS
We thank all the patients and health care workers who consented to take part
in this study. We are grateful to CVC Capital Partners, the Evelyn Trust (20/75),
Addenbrooke’s Charitable Trust, Cambridge University Hospitals (12/20A), the16 Immunity 54, 1–19, June 8, 2021NIHR Cambridge Biomedical Research Centre, and the UKRI/NIHR through
the UK Coronavirus Immunology Consortium (UK-CIC) for their financial sup-
port. Further support: K.G.C.S.: Wellcome Investigator Award (200871/Z/16/
Z); M.P.W.: Wellcome Senior Clinical Research Fellowship (108070/Z/15/Z);
C.H.: Wellcome COVID-19 Rapid Response DCF and the Fondation Botnar;
N.M.: MRC (CSF MR/P008801/1), NHSBT (WPA15-02), and Addenbrooke’s
Charitable Trust, (grant ref. to 900239 NJM); I.G.G.: Wellcome Senior Fellow-
ship and Wellcome grant (Ref: 207498/Z/17/Z); P.J.L.: Wellcome Trust Prin-
cipal Research Fellowship (084957/Z/08/Z) and MRC (MR/V011561/1);
J.K.N.: The Spinnaker Healthcare Research Trust and the McCusker Founda-
tion as part of Australian National Phenome Centre. P.K. is the recipient of a
Jacquot Research Entry Scholarship of the Royal Australasian College of Phy-
sicians Foundation. We would like to thank the NIHR Cambridge Clinical
Research Facility outreach team for enrollment of patients; the NIHR Cam-
bridge Biomedical Research Centre Cell Phenotyping Hub and the CRUK
Cambridge Institute flow cytometry core facility for flow and mass cytometry;
and the Cambridge NIHR BRC Stratified Medicine Core Laboratory NGS Hub
(supported by an MRC Clinical Infrastructure Award) for RNA sequencing.AUTHOR CONTRIBUTIONS
Conceptualization, K.G.C.S., J.R.B., P.A.L., and C.H.; Methodology, L.B., L.T.,
M.R.W., I.G.G., and R.D.; Software, K.H.; Validation, L.T.; Formal analysis,
L.B., F.M., L.T., A.H., P.K., and H.R.; Data curation, F.M., A.H., P.K., and
L.T.; Investigation, L.B., F.M., L.T., P.K., A.D.S., O.H., M.D.M., P.P.G.,
M.R.W., I.G.G., M.H., F.J.C., R.D., J.K.N., and E.J.M.T.; Visualization, A.H.
and P.K.; Project administration, L.B., F.M., L.T., B.J.D., C.S., and A.E.; Fund-
ing acquisition, P.J.L., N.K., J.R.B., C.H., G.D., M.P.W., P.A.L., and K.G.C.S.;
Supervision, J.R.B., P.A.L., and K.G.C.S.; Resources, A.M.P., M.T., M.P.W.,
and N.J.M.; Writing – original draft, K.G.C.S., P.A.L., P.J.L., and C.H.; Writing –
review & editing, L.B., F.M., A.H., L.T., P.K., H.R., B.J.D., A.D.S., O.H., M.D.M.,
P.P.G., F.J.C., R.D., K.H., S.B., R.K.G., J.K.N., C.S., A.E., A.M.P., E.J.M.T.,
N.K., P.J.L., N.J.M., S.R., J.E.D.T., M.P.W., B.G., M.T., C.H., J.R.B., G.D.,
M.R.W., M.H., I.G.G., P.A.L., and K.G.C.S.DECLARATION OF INTERESTS
The authors declare they have no competing interests. E.J.M. Toonen is an
employee of Hycult Biotechnology b.v.
Received: December 21, 2020
Revised: March 13, 2021
Accepted: May 11, 2021
Published: May 16, 2021
REFERENCES
Akbari, P., Vuckovic, D., Jiang, T., Kundu, K., Kreuzhuber, R., Bao, E.L., Mayer,
L., Collins, J.H., Downes, K., Georges, M., et al. (2020). Genetic Analyses of
Blood Cell Structure for Biological and Pharmacological Inference. bioRxiv.
https://doi.org/10.1101/2020.01.30.927483.
Antin, J.H., Emerson, S.G., Martin, P., Gadol, N., and Ault, K.A. (1986). Leu-1+
(CD5+) B cells. A major lymphoid subpopulation in human fetal spleen: pheno-
typic and functional studies. J. Immunol. 136, 505–510.
Arunachalam, P.S., Wimmers, F., Mok, C.K.P., Perera, R.A.P.M., Scott, M.,
Hagan, T., Sigal, N., Feng, Y., Bristow, L., Tak-Yin Tsang, O., et al. (2020).
Systems biological assessment of immunity to mild versus severe COVID-19
infection in humans. Science 369, 1210–1220.
Banchereau, R., Cepika, A.M., Banchereau, J., and Pascual, V. (2017).
Understanding Human Autoimmunity and Autoinflammation Through
Transcriptomics. Annu. Rev. Immunol. 35, 337–370.
Bantug, G.R., Galluzzi, L., Kroemer, G., and Hess, C. (2018). The spectrum of
T cell metabolism in health and disease. Nat. Rev. Immunol. 18, 19–34.
Berg, R.E., Crossley, E., Murray, S., and Forman, J. (2003). Memory CD8+
T cells provide innate immune protection against Listeria monocytogenes in
the absence of cognate antigen. J. Exp. Med. 198, 1583–1593.
ll
OPEN ACCESSArticle
Please cite this article in press as: Bergamaschi et al., Longitudinal analysis reveals that delayed bystander CD8+ T cell activation and early immune
pathology distinguish severe COVID-19 from mild disease, Immunity (2021), https://doi.org/10.1016/j.immuni.2021.05.010Bernardes, J.P., Mishra, N., Tran, F., Bahmer, T., Best, L., Blase, J.I., Bordoni,
D., Franzenburg, J., Geisen, U., Josephs-Spaulding, J., et al. (2020).
Longitudinal Multi-omics Analyses Identify Responses of Megakaryocytes,
Erythroid Cells, and Plasmablasts as Hallmarks of Severe COVID-19.
Immunity 53, 1296–1314.
Boes, M., Prodeus, A.P., Schmidt, T., Carroll, M.C., and Chen, J. (1998). A crit-
ical role of natural immunoglobulin M in immediate defense against systemic
bacterial infection. J. Exp. Med. 188, 2381–2386.
Borchers, M.T., Wesselkamper, S.C., Curull, V., Ramirez-Sarmiento, A.,
Sánchez-Font, A., Garcia-Aymerich, J., Coronell, C., Lloreta, J., Agusti, A.G.,
Gea, J., et al. (2009). Sustained CTL activation by murine pulmonary epithelial
cells promotes the development of COPD-like disease. J. Clin. Invest. 119,
636–649.
Carissimo, G., Xu, W., Kwok, I., Abdad, M.Y., Chan, Y.H., Fong, S.W., Puan,
K.J., Lee, C.Y., Yeo, N.K., Amrun, S.N., et al. (2020). Whole blood immunophe-
notyping uncovers immature neutrophil-to-VD2 T-cell ratio as an early marker
for severe COVID-19. Nat. Commun. 11, 5243.
Cella, M., Jarrossay, D., Facchetti, F., Alebardi, O., Nakajima, H.,
Lanzavecchia, A., and Colonna, M. (1999). Plasmacytoid monocytes migrate
to inflamed lymph nodes and produce large amounts of type I interferon.
Nat. Med. 5, 919–923.
Chen, Z., and JohnWherry, E. (2020). T cell responses in patients with COVID-
19. Nat. Rev. Immunol. 20, 529–536.
Chen, E.Y., Tan, C.M., Kou, Y., Duan, Q.,Wang, Z., Meirelles, G.V., Clark, N.R.,
and Ma’ayan, A. (2013). Enrichr: interactive and collaborative HTML5 gene list
enrichment analysis tool. BMC Bioinformatics 14, 128.
Cheng, X., Liu, Y.-M., Li, H., Zhang, X., Lei, F., Qin, J.-J., Chen, Z., Deng, K.-Q.,
Lin, L., Chen, M.-M., et al. (2020). Metformin Is Associated with Higher
Incidence of Acidosis, but Not Mortality, in Individuals with COVID-19 and
Pre-existing Type 2 Diabetes. Cell Metab. 32, 537–547.
Collier, D.A., Assennato, S.M., Warne, B., Sithole, N., Sharrocks, K., Ritchie,
A., Ravji, P., Routledge, M., Sparkes, D., Skittrall, J., et al.; CITIID-NIHR
COVID BioResource Collaboration (2020). Point of Care Nucleic Acid Testing
for SARS-CoV-2 in Hospitalized Patients: A Clinical Validation Trial and
Implementation Study. Cell Rep. Med. 1, 100062.
Daly, J.L., Simonetti, B., Klein, K., Chen, K.E., Williamson, M.K., Antón-
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Antibodies
Anti-human CCR4 PEVio770 (REA279) Miltenyi RRID:AB_2655909
Anti-human CCR5 AF647 (HEK/1/85a) Biolegend RRID:AB_528760
Anti-human CCR6 PECy7 (G034E3) BioLegend RRID:AB_10916518
Anti-human CCR7 BV650 (G043H7) BioLegend RRID:AB_2563867
Anti-human CCR7 APC-fire (G043H7) BioLegend RRID:AB_2750147
Anti-human CD11c AF700 (B-ly6) BD RRID:AB_10612006
Anti-human CD123 BV786 (7G3) BD RRID:AB_2738662
Anti-human CD127 PECy5 (eBioRDR5) Thermo RRID:AB_2043801
Anti-human CD127 PerCP efluor710 (eBioRDR5) Thermo RRID:AB_2762464
Anti-human CD14 BV711 (MjP9) BD RRID:AB_2744290
Anti-human CD14 BV510 (63D3) BioLegend RRID:AB_2716229
Anti-human CD141 BV605 (1A4) BD RRID:AB_2740151
Anti-human CD15 BV510 (W6D3) BioLegend RRID:AB_2563400
Anti-human CD16 BUV496 (3G8) BD RRID:AB_2870224
Anti-human CD161 PE (HP-3G10) BioLegend RRID:AB_1501083
Anti-human CD163 PE-CF594 (GHI/61) BD RRID:AB_2737711
Anti-human CD19 BUV496 (SJ25C1) BD RRID:AB_2870221
Anti-human CD193 BV510 (5E8) BioLegend RRID:AB_2571977
Anti-human CD1c AF647 (F10/21A3) BD RRID:AB_2744318
Anti-human CD20 BUV805 (2H7) BD RRID:AB_2870192
Anti-human CD24 BB700 (ML5) BD RRID:AB_2744333
Anti-human CD25 PE (BC96) Thermo RRID:AB_1659682
Anti-human CD27 BV711 (O323) BioLegend RRID:AB_2563809
Anti-human CD28 BV785 (CD28.2) BioLegend RRID:AB_2632607
Anti-human CD28 BUV805 (L293) BD RRID:AB_2872889
Anti-human CD3 BUV395 (SK7) BD RRID:AB_2744382
Anti-human CD3 BUV661 (UCHT1) BD RRID:AB_2870239
Anti-human CD3 BV510 (UCHT1) BioLegend RRID:AB_2563468
Anti-human CD303 PE-Vio770 (REA693) Miltenyi RRID:AB_2657198
Anti-human CD304 PE (U21-1283) BD RRID:AB_2744361
Anti-human CD32 BB700 (FLI8.26) BD RRID:AB_2871430
Anti-human CD38 BUV661 (HIT2) BD RRID:AB_2870242
Anti-human CD39 BV421 (A1) BioLegend RRID:AB_2564575
Anti-human CD39 APC-fire (A1) BioLegend RRID:AB_2650839
Anti-human CD4 BUV496 (SK3) BD RRID:AB_2870220
Anti-human CD40 BUV395 (5C3) BD RRID:AB_2739110
Anti-human CD45 BUV805 (HI30) BD RRID:AB_2870179
Anti-human CD45RA BV570 (HI100) BioLegend RRID:AB_2563813
Anti-human CD45RA BUV805 (HI100) BD RRID:AB_2871317
Anti-human CD56 FITC (MEM188) Thermo RRID:AB_10372519
Anti-human CD69 BV650 (FN50) BioLegend RRID:AB_2563158
Anti-human CD71 BV650 (CY1G4) BioLegend RRID:AB_2687103
Anti-human CD73 Brilliant Violet 785 (AD2) BioLegend RRID:AB_2687234
Anti-human CD73 BV785 (AD2) BioLegend RRID:AB_2687234
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Anti-human CD80 PECy5 (L307.4) BD RRID:AB_397239
Anti-human CD86 BUV737 (FUN-1) BD RRID:AB_2814790
Anti-human CD86 PECy7 (BU63) BioLegend RRID:AB_2728392
Anti-human CD8b BV480 (2ST8.5H7) BD RRID:AB_2743598
Anti-human CD95 BUV737 (DX2) BD RRID:AB_2870117
Anti-human CRTh2 PE-dazzle (BM16) BioLegend RRID:AB_2572053
Anti-human CXCR5 APC-R700 (RF8B2) BD RRID:AB_2739103
Anti-human FoxP3 APC (236A/E7) Thermo RRID:AB_10804651
Anti-human GLUT1 AF647 (202915) BD RRID:AB_2869787
Anti-human Helios Pedazzle (22F6) BioLegend RRID:AB_2565797
Anti-human HLA-DR APC-H7 (G46-6) BD RRID:AB_10611876
Anti-human HLADR BV605 (L243) BioLegend RRID:AB_2561913
Anti-human KLRG1 FITC (REA261) Miltenyi RRID:AB_2652570
Anti-human PD-1 BV421 (EH12.2H7) BioLegend RRID:AB_10960742
Anti-human TCR Vg9 AF700 (B3) Biolegend RRID:AB_2814207
Anti-human TCR-DV1 PECy7 (TS8.2) Thermo RRID:AB_2762454
Anti-human TCR-DV2 PerCPCy5.5 (B6) BioLegend RRID:AB_2687330
Anti-human TCRgd BUV737 (11F2) BD RRID:AB_2872944
Anti-human TCRV7.2 BV711 (3C10) BioLegend RRID:AB_2629680
Anti-human Vb11 APCVio770 (REA559) Miltenyi RRID:AB_2653747
Zombie Aqua BioLegend Cat#423101
Zombie Yellow BioLegend Cat#423103
Anti-human CD3 FITC (UCHT1) BioLegend RRID:AB_2562046
Anti-human CD4 PE (RPA-T4) BioLegend RRID:AB_2562053
Anti-human CD8a PerCP-Cy5.5 (RPA-8a) BioLegend RRID:AB_1575074
Fixable Far Red Dead Cell Stain Kit Thermo Cat#423109
Chemicals, peptides, and recombinant proteins
Spike SARS-CoV-2 peptide prot-S Miltenyi Biotec Cat#130-126-701
Spike SARS-CoV-2 peptide Prot-S1 Miltenyi Biotec Cat#130-127-048
Nucleocapsid SARS-CoV-2 peptide Miltenyi Biotec Cat#130-126-699
Membrane SARS-CoV-2 peptide Miltenyi Biotec Cat#130-126-703
Staphylococcus Enterotoxin B (SEB) Sigma Aldrich Cat#S4881-1MG
Phytohaemagglutinin (PHA) Sigma Aldrich Cat#L1668-5MG
anti-CD3 Mabtech AB Cat#3605-1-1000
Spike SARS-CoV-2 protein Xiong et al., 2020 N/A
SARS-CoV-2 neutralisation assay Gerber, et al., 2021 N/A
Critical commercial assays
6-color TBNK Reagent with BD Trucount Tubes BD RRID:AB_2868707
Maxpar Direct Immune Profiling Assay Fluidigm Cat#201325
Human IFNg FLUOROSPOT Mabtech AB Cat#X-01A-10
hIFN-g HS LxPA MAG R&D systems/ Biotechne Cat#LHSCM285B
Human IL-1b Mag Bead Set R&D systems/ Biotechne Cat#LHSCM201
Human IL-6 Mag Bead Set R&D systems/ Biotechne Cat#LHSCM206
Human IL-10 Mag Bead Set R&D systems/ Biotechne Cat#LHSCM217
Human TNF-a Mag Bead Set R&D systems/ Biotechne Cat#LHSCM210
Base Kit, HS Cytokine A, Mag R&D systems/ Biotechne Cat#LHSCM000
Fluorocell RET Sysmex Corporation Cat#BN-337-547
C3a, Human, ELISA kit Hycult Biotech Cat#HK354
C3c, Human, ELISA kit Hycult Biotech Cat#HK368
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TCC, Human, ELISA kit Hycult Biotech Cat#HK328
SMARTer Stranded Total RNA-Seq
v2 - Pico Input Mammalian kit
Takara Cat#634414
Deposited data
CITE-seq data Stephenson et al., 2021,
Cambridge cohort
Array Express:E-MTAB-10026
Absolute cell count, Whole blood RNA-seq,
cytokine and complement measurements,
SARS-CoV-2 specific antibody titers
This paper https://www.covid19cellatlas.org/patient/citiid/
Flow cytometry data: B cell and Treg panels This paper Flow Repository:FR-FCM-Z3XQ
Flow cytometry data: Monocyte panel This paper Flow Repository:FR-FCM-Z3SR
Flow cytometry data: Conventional T cell panel This paper Flow Repository:FR-FCM-Z3ST;
Flow cytometry data: non-conventional T cell panel This paper Flow Repository:FR-FCM-Z3SS
Whole blood RNA-seq data This paper EGA:EGAS00001005332
Software and algorithms
Maxpar Pathsetter software v2.0.45 Verity Software House,
Topsham, ME
N/A
FlowJo v10.2 FlowJo LLC N/A
CyTOF Software v6.7.1016 Fluidigm N/A
AID EliSpot v7 software Autoimmun Diagnostika
GmbH, Strasberg, Germany
N/A
FastQC v.0.11.8 Babraham Bioinformatics, UK https://www.bioinformatics.babraham.ac.uk/
projects/fastqc/
Trim_galore v.0.6.4 Babraham Bioinformatics, UK https://www.bioinformatics.babraham.ac.uk/
projects/trim_galore/
BBMap v.38.67 BBMap - Bushnell B. https://sourceforge.net/projects/bbmap/
HISAT2 v.2.1.0 Kim et al., 2019 http://daehwankimlab.github.io/hisat2/
R R Core Team, 2015 N/A
pathway-level information extractor PLIER http://gobie.csb.pitt.edu/PLIER
Gene set enrichment analysis (GSEA) Broad Institute https://www.gsea-msigdb.org/gsea/index.jsp
Other
XN-1000 hematology analyzer Sysmex N/A
Symphony X-50 BD N/A
Helios mass cytometer Fluidigm N/A
AID iSpot reader Oxford Biosystems N/A
Luminex Bio-Plex, Bio-Rad, UK N/A
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Lead contact
Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact Prof Ken-
neth Smith (kgcs2@cam.ac.uk).
Materials availability
This study did not generate new unique reagents.
Data and code availability
The datasets generated during this study are available at NIHR CITIID COVID-19 Cohort (https://www.covid19cellatlas.org/patient/
citiid/). In addition, whole blood RNA-seq data are available at European Genome-phenome Archive (EGA, ID:EGAS00001005332),
and flow cytometry data are available at FLOW Repository (IDs: FR-FCM-Z3XQ, FR-FCM-Z3SR, FR-FCM-Z3ST, FR-FCM-Z3SS).
CITE-seq processed data are available to download from Array Express using accession number E-MTAB-10026.e3 Immunity 54, 1–19.e1–e8, June 8, 2021
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Human subjects
Study participants were recruited between 31/3/2020 and 20/7/2020 from patients attending Addenbrooke’s Hospital with a sus-
pected or nucleic acid amplification test (NAAT) confirmed diagnosis of COVID-19 (including point of care testing (Collier et al.,
2020;Mlcochova et al., 2020)), patients admitted to Royal Papworth Hospital NHS Foundation Trust or Cambridge and Peterborough
Foundation Trust with a confirmed diagnosis of COVID-19, together with Health Care Workers identified through staff screening as
PCR positive for SARS-CoV-2 (Rivett et al., 2020). Detailed information on the patients (age, gender, and clinical features) can be
found in Table S1. Controls were recruited among hospital staff attending Addenbrooke’s serology screening program, and selected
to cover the whole age spectrum of COVID-19 positive study participants, across both genders. Only controls with negative serology
results (45 out of 47) were subsequently included in the study. Recruitment of inpatients at Addenbrooke’s Hospital and Health Care
Workers was undertaken by theNIHRCambridge Clinical Research Facility outreach teamand theNIHRBioResource research nurse
team. Ethical approval was obtained from the East of England – Cambridge Central Research Ethics Committee (‘‘NIHR
BioResource’’ REC ref 17/EE/0025, and ‘‘Genetic variation AND Altered Leucocyte Function in health and disease - GANDALF’’
REC ref 08/H0308/176). All participants provided informed consent.
Inpatients were sampled at study entry, and then at regular intervals as long as they remained admitted to hospital (approximately
weekly up to 4 weeks, and then every 2 weeks up to 12 weeks). Discharged patients were invited to provide a follow-up sample
4-8 weeks after study enrolment. Health care workers were sampled at study entry, and subsequently after approximately 2 and
4 weeks. At each time-point, blood samples were drawn in EDTA, sodium citrate, serum and PAXgene Blood RNA tubes (BD
Biosciences) and processed by the CITIID-NIHR COVID BioResource Collaboration group (Document S1).
Cell lines
HEK293 T cells (a female cell line) were a kind gift from Paul Lehner, authenticated by STR profiling (Menzies et al., 2018; Miles et al.,
2017). They were cultured in DMEM supplemented with 10% fetal calf serum (FCS), 100 units/mL penicillin, and 0.1 mg/ml strepto-
mycin at 37 C in 5% CO2.
Virus
The virus used in this study was the clinical isolate SARS-CoV428 2/human/Liverpool/REMRQ0001/2020, a kind gift from Ian
Goodfellow (University of Cambridge), isolated by Lance Turtle (University of Liverpool), and David Matthews and Andrew Davidson
(University of Bristol) (Daly et al., 2020; Patterson et al., 2020).
METHOD DETAILS
Clinical data collection
Clinical data were retrospectively collected by review of medical charts and entered into spreadsheets or Castor EDC, a cloud-based
clinical datamanagement system. Available laboratory test results and administered in-patientmedicationswere extracted fromEpic
electronic health records (Addenbrooke’s Hospital) and from MetaVision ICU (RPH ITU). Data were merged from the various data
sources using R version 3.6 and the R packages readr (1.3.1), openxlsx (4.1.4), dplyr (0.8.3), tidyr (1.0.2) and lubridate (1.7.4).
Health care workers were classified in 2 groups (A and B) according to whether they were asymptomatic (group A) or had possible
COVID-19 symptoms (group B) at the time of PCR testing. For this purpose, new-onset fever (> 37.8 C), cough, loss of sense of smell,
hoarseness, nasal discharge or congestion, shortness of breath, wheeze, headache, muscle aches, nausea, vomiting and diarrhea
were considered as possible COVID-19 symptoms.
Participants in group Awere further sub-grouped according to whether they were completely asymptomatic (n = 8), or had had any
of the above COVID-19 symptoms before PCR testing (n = 10, median time from symptoms to COVID-19 PCR test 26 days, range
9-42 days).
Group B participants included both staff who were self-isolating because of COVID-19 symptoms (n = 30), and staff members who
were reporting fit for duty, but had some symptoms that did not reach the threshold for self-isolation at that time (n = 10).
Hospital patients were assigned to 3 severity groups, mainly reflecting the maximum intensity of respiratory support for COVID-19
received during their hospital stay:
d group C: did not receive any supplemental oxygen. Five patients were discharged soon after initial diagnosis and assessment
but followed up as part of the study.
d group D: received supplemental oxygen using low flow nasal prongs, simple face mask, Venturi mask or non-rebreather
face mask.
d group E: received any of non-invasive ventilation (NIV), mechanical ventilation or ECMO. Patients who received supplemental
oxygen (but no ventilation) and deceased in hospital were also assigned to group E.
In patients who were already established on home NIV for chronic respiratory failure, NIV delivered as per the home prescription
(e.g., nocturnal) was not considered for the purpose of classification. Moreover, oxygen requirements that were clearly not related toImmunity 54, 1–19.e1–e8, June 8, 2021 e4
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non-COVID-19 indications (ascitic splinting in decompensated cirrhosis in one case, and recovery from anesthesia after orthopedic
surgery in the other) were assigned to group C. Cases in group C were further sub-classified according to chest radiology results
(X-ray and, if available, CT scan), as:
d abnormal radiology: chest X-ray/ CT scan showed changes compatible with COVID-19
d normal radiology: chest X-ray/ CT scan did not show any abnormality compatible with COVID-19 (reported as normal or
showing lung changes diagnostic of conditions other than COVID-19).
Immunological parameters were analyzed according to time since onset of symptoms, or otherwise time since positive SARS-
CoV-2 NAAT (in group A and in 4 asymptomatic patients in group C). Seven cases admitted to hospital for COVID-19 had no date
of onset of symptoms documented in the medical records. In these cases, the date of onset of symptoms was estimated as follows:
hospital admission date - median time from symptoms to hospital admission in patients admitted for COVID-19.
Following clinician review, 6 cases were considered not classifiable, due to complex concomitant pathologies that coexisted with
COVID-19 and dominated the clinical picture, confounding the interpretation of clinical outcome. These cases were not included in
any analyses; more details are reported in Table S2. Data S1 summarizes the timing of research samples and clinical trajectories for
volunteers in severity groups C, D and E included in the analysis.
Peripheral blood mononuclear cell preparation and flow immunophenotyping
Each participant provided 27 mL of peripheral venous blood collected into 9 mL sodium citrate tube. Peripheral blood mononuclear
cells (PBMCs) were isolated using Leucosep tubes (Greiner Bio-One) with Histopaque 1077 (Sigma) by centrifugation at 800x g for
15 min at room temperature. PBMCs at the interface were collected, rinsed twice with autoMACS running buffer (Miltenyi Biotech)
and cryopreserved in FBS with 10% DMSO. All samples were processed within 4 h of collection.
Five distinct antibody cocktails (Data S4) were used to label approximately 106 PBMCs using standard methods. T regulatory cells
were fixed and permeabilized following surface staining prior to the addition of intracellular antibodies. Samples were stored at 4C
and acquired within 4 h using a 5-laser BD Symphony X-50 flow cytometer. Single color compensation tubes (BD CompBeads) or
cells were prepared for each of the fluorophores used and acquired at the start of each flow cytometer run.
For direct enumeration of T, B and NK cells, an aliquot of whole blood (50 ml) was added to BD TruCount tubes with 20ml- BD Mul-
titest 6-color TBNK reagent (BD Biosciences) and processed as per the manufacturer’s instructions.
Samples were gated in FlowJo v10.2 according to the schema set out in Data S4. The number of cells falling within each gate was
recorded. For analysis, these were expressed as an absolute concentration of cells per ml, calculated using the proportions of
daughter populations present within the parent population determined using the BD TruCountsystem.
CyTOF
The protocol used to isolate PBMCs led to an impaired recovery of the different monocyte populations, specifically intermediate and
non-classical monocytes (Figure S2). To extend our analysis to these and other granulocyte populations we performed mass cyto-
metric analysis on a subgroup of patients and healthy controls (249 samples). Briefly, whole blood samples (270ml) were stained using
the Fluidigm Maxpar Direct Immune Profiling Assay according to the manufacturer’s instructions. Samples were cryopreserved at
80C following staining and thawed for analysis within 4 weeks. Samples were acquired using a Fluidigm Helios mass cytometer
and normalized using the CyTOF Software v6.7.1016. FCS files generated were analyzed using the Maxpar Pathsetter software
v2.0.45 (Verity Software House, Topsham, ME). Standard settings were used to generate immune cell frequencies for 37 immune
cell populations. Absolute cell numbers were calculated using the proportions of these immune cell populations within the parent
populations determined by BD TruCount.
Reticulocyte counts
Reticulocyte numbers were measured using a Sysmex XN-1000 hematology analyzer according to manufacturer instruction and as
previously described (Akbari et al., 2020). Briefly, Sysmex technology uses three signals to define the physiological and structural
properties of cells and to distinguish reticulocytes from the other blood cells: forward scatter, side scatter and side fluorescent light.
Thesemeasurements rely on the similar electromagnetic radiation and fluid dynamics concepts of a flow cytometer; reticulocyte spe-
cific fluorescent probes are covered by a patent deposited by Sysmex Corporation (i.e., Fluorocell RET, cat# BN-337-547).
Reticulocyte Ratio:
RET% =
Particle count ˛ reticulocyte zone
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Complement activation was assessed by measuring C3 activation products (C3a and C3c) together with the terminal complement
complex (TCC) as an end product of the complement cascade. Concentrations of these complement components were measured in
EDTA plasma from patients using commercially available enzyme-linked immunosorbent assays (ELISA) kits (HK354 (C3a), HK368
(C3c), HK328 (TCC), Hycult Biotech, Uden, the Netherlands) according to the manufacturer’s protocols.
CRP
High sensitivity CRP was measured using the standard assay by the Core Biochemical Assay Laboratory (CBAL) at Cambridge Uni-
versity Hospitals NHS Foundation Trust.
Cytokines
IL-6, IL-10, IL-1b, TNF-a and IFN-g were measured in serum from patients and HCs by high sensitivity Base Kit HS Cytokine A Mag
(cat# LHSCM000, R&D Systems / Biotechne) on a Luminex analyzer (Bio-Plex, Bio-Rad, UK) as standard clinical assay performed by
the Clinical Immunology Laboratory at the Department of Biochemistry and Immunology, Addenbrooke’s Hospital Cambridge.
IFN-m FLUOROSPOT assays
Frozen PBMCs were rapidly thawed, and the freezing medium was diluted into 10ml of TexMACS media (Miltenyi Biotech), centri-
fuged and resuspended in 10ml of fresh media with 10U /ml DNase (Benzonase, Merck-Millipore via Sigma-Aldrich), PBMCs
were incubated at 37C for 1 h, followed by centrifugation and resuspension in fresh media supplemented with 5%Human AB serum
(Sigma Aldrich) before being counted. PBMCs were stained with 2ml of each antibody: anti-CD3- fluorescein isothiocyanate (FITC),
clone UCHT1; anti-CD4- phycoerythrin (PE), clone RPA-T4; anti-CD8a- peridinin-chlorophyll protein - cyanine 5.5 (PerCP Cy5.5),
clone RPA-8a (all BioLegend, London, UK), LIVE/DEAD Fixable Far Red Dead Cell Stain Kit (Thermo Fisher Scientific). PBMC phe-
notyping was performed on the BD Accuri C6 flow cytometer. Data were analyzed with FlowJo v10 (Becton Dickinson, Wokingham,
UK). 1.5 to 2.5 3 105 PBMCs were incubated in pre-coated Fluorospot plates (Human IFN-g FLUOROSPOT (Mabtech AB, Nacka
Strand, Sweden)) in triplicate with peptide mixes specific for Spike, Nucleocapsid andMembrane proteins of SARS-CoV-2 (final pep-
tide concentration 1mg/ml/peptide, Miltenyi Biotech) and an unstimulated and positive control mix (containing anti-CD3 (Mabtech
AB), Staphylococcus Enterotoxin B (SEB), Phytohaemagglutinin (PHA) (all Sigma Aldrich)) at 37C in a humidified CO2 atmosphere
for 48 h. The cells and medium were decanted from the plate and the assay developed following the manufacturer’s instructions.
Developed plates were read using an AID iSpot reader (Oxford Biosystems, Oxford, UK) and counted using AID EliSpot v7 software
(Autoimmun Diagnostika GmbH, Strasberg, Germany). All data were then corrected for background cytokine production and ex-
pressed as SFU/Million CD3+T cells.
SARS-CoV-2 serology
Quantification of Spike SARS-CoV-2 specific antibodies was performed by ELISA as described by Xiong X et al. (Xiong et al., 2020).
Briefly, serum samples collected at time of enrolment in the study and at the 4-8 week follow-up visit were first screened for positivity
and then antibody titers were determined by an end-point analysis. AUC values were calculated in R (3.6.3) using the flux (0.3-0)
package. Kruskal–Wallis test was used to calculate p values among the different disease severities.
SARS-CoV-2 neutralisation assay
The virus used in this studywas the clinical isolate SARS-CoV-2/human/Liverpool/REMRQ0001/2020, a kind gift from IanGoodfellow
(University of Cambridge), isolated by Lance Turtle (University of Liverpool) and David Matthews and Andrew Davidson (University of
Bristol) (Daly et al., 2020; Patterson et al., 2020).
Sera were heat-inactivated at 56C for 30 min, then frozen in aliquots at 80C. Neutralising antibody titers at 50% inhibition
(NT50s) were measured as previously described (Gerber et al., 2021).
In brief, HEK293T reporter cells expressing Renilla luciferase (Rluc) and SARS-CoV-2 Papain-like protease-activatable circularly
permuted firefly luciferase (FFluc) were seeded in flat-bottomed 96-well plates. The next day, SARS-CoV-2 viral stock (MOI = 1) was
pre-incubated with a 3-fold dilution series of each serum for 2 h at 37C, then added to the cells. After 24 h, cells were lysed in Dual-
Glo Luciferase Buffer (Promega) diluted 1:1 with PBS and 1%NP-40. Lysates were transferred to white half-area 96-well plates, and
infectious virus quantitated as the ratio of FFluc/Rluc activity measured using the Dual-Glo kit (Promega) according to the manufac-
turer’s instructions.
Experiments were conducted in duplicate. To obtain NT50s, FFluc/Rluc ratios were analyzed using the Sigmoidal, 4PL, X is
log(concentration) function in GraphPad Prism.
Whole blood bulk RNA-Seq
Whole blood RNAwas extracted from PAXgene Blood RNA tubes (BD Biosciences) of 188 COVID-19 patients, at up to 2 time points,
and 42 healthy volunteers. RNA-Sequencing libraries were generated using the SMARTer Stranded Total RNA-Seq v2 - Pico Input
Mammalian kit (Takara) using 10ng RNA as input following the manufacturer’s protocol. Libraries were pooled together (n = 96) and
sequenced using 75bp paired-end chemistry across 4 lanes of a Hiseq4000 instrument (Illumina) to achieve 10million reads per sam-
ple. Read quality was assessed using FastQC v.0.11.8 (BabrahamBioinformatics, UK), and SMARTer adaptors trimmed and residualImmunity 54, 1–19.e1–e8, June 8, 2021 e6
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nell B. - https://sourceforge.net/projects/bbmap/)), respectively. Alignment was performed using HISAT2 v.2.1.0 (Kim et al., 2019)
against the GRCh38 genome, achieving a greater than 95% alignment rate. Count matrices were generated using featureCounts
(Rsubreads package - (Liao et al., 2020) and stored as a DGEList object (EdgeR package (Robinson et al., 2010) for further analysis.
All downstream data handling was performed in R (RCore Team, 2015). Counts were filtered using filterByExpr (EdgeR) with a gene
count threshold of 10 CPM and the minimum number of samples set at the size of the smallest disease group. Library counts were
normalized using calcNormFactors (EdgeR) using themethod ‘weighted trimmedmean of M-values’. The function ‘voom’ (Law et al.,
2014) was applied to the data to estimate the mean-variance relationship, allowing adjustment for heteroscedasticity.
Single cell RNA-seq
CITE-seq datawere generated from frozen PBMCs as described by Stephenson et al. (Stephenson et al., 2021). Briefly, after thawing,
pools of 4 samples were generated by combined 500,000 viable cells per individual (total of 2 million cells per pool). TotalSeq-C anti-
body cocktail (BioLegend 99813) was used to perform cell surfacemarker staining on 500,000 cells per pool. 50,000 live cells (up to a
maximum of 60,000 total cells) for each pool were processed using Single Cell V(D)J 5¢ version 1.1 (1000020) together with Single
Cell 5¢ Feature Barcode library kit (1000080), Single Cell V(D)J Enrichment Kit, Human BCells (1000016) and Single Cell V(D)J Enrich-
ment Kit, Human T Cells (1000005) (10xGenomics) according to the manufacturer’s protocols. Samples were sequenced on Nova-
Seq 6000 (Illumina) using S1 flowcells. Droplet libraries were processed using Cellranger v4.0. Reads were aligned to the GRCh38
human genome concatenated to the SARS-Cov-2 genome (NCBI SARS-CoV-2 isolate Wuhan-Hu-1) using STAR (Dobin et al., 2013)
and unique molecular identifiers (UMIs) deduplicated. CITE-seq UMIs were counted for GEX and ADT libraries simultaneously to
generate feature X droplet UMI count matrices.
QUANTIFICATION AND STATISTICAL ANALYSIS
All statistical analyses were conducted using custom scripts in R (R Core Team, 2015). Absolute cell counts (cells/uL) were offset
by +1 to allow subsequent log2 transformation of zero counts. Where shown, time measures represent time from symptom onset
(for severity groups B, C, D and E) or first positive COVID-19 swab (group A). Unless otherwise specified, longitudinally collected
data was grouped by bins of 7 or 12 days. Pairwise statistical comparison of absolute cell counts, CRP or serummeasures between
individuals in a given severity group at a given time bin and HCs, or between severity groups, was conducted byWilcoxon test unless
otherwise specified. For analyses involving repeated-measures, false discovery rate corrected (Benjamini & Hochberg) p value were
reported. For individuals sampled more than once within a given time bin, data from the earliest blood collection was used.
Cell subset deconvolution of the whole blood RNA-Seq dataset was performed using pathway-level information extractor (PLIER)
(http://gobie.csb.pitt.edu/PLIER). Latent factors were generated by leveraging off pre-existing knowledge of cell specific pathways.
To better understand the relationship between gene expression and clinical severity, weighted gene co-expression network analysis
was carried out using the WGCNA package (Langfelder and Horvath, 2008) in R. Briefly, a signed adjacency matrix was generated
and a soft thresholding power was chosen to impose approximate scale-free topology. Modules were identified from the resulting
topological overlap matrix with a specified minimum module size of n = 30. Modules were summarized using singular value decom-
position, and the resultingmodule eigengene correlatedwith clinical traits. Significance of the correlation between a given clinical trait
and a modular eigengene was assessed using linear regression with Bonferroni adjustment to correct for multiple testing. Modules
were annotated using Enrichr (Chen et al., 2013). Longitudinal mixedmodeling of genemodule changes over time ðyijÞwas conducted
using the nlme package in R (Pinheiro et al., 2021), including time (tij) with a quadratic trend and disease severity category or unsu-
pervised cluster ids (Xj) as fixed effects, and sampled individuals as random effects (uj):
yij = b0j + b1j tij + b2j t
2










i.e., using the lme formula:
module_eigenvalue  ðtime + Iðtimê2ÞÞ  category; random =  1jsubject
Gene set enrichment analysis (GSEA) (Subramanian et al., 2005) was used to identify biological pathways enriched in COVID-19
severity groups relative to healthy controls. Briefly, a list of ranked genes, determined by Signal-To-Noise ratio, was generated. An
enrichment score was calculated, determined by how often genes from the geneset of interest appeared at the top or the bottom of
the pre-ranked set of genes with the enrichment score representing the maximum deviation from zero. To assess statistical signif-
icance, an empirical phenotype- based permutation test was run, where a collection of enrichment scores was generated from the
random assignment of phenotype to samples and used to generate a null distribution. To account for multiple testing, an FDR rate
q < 0.20 was deemed significant. A leading edge analysis was performed to determine the genes contributing the most to the enrich-
ment of a given pathway and was subsequently illustrated in a heatmap. Hallmark gene sets from theMolecular Signatures Database
(https://www.broadinstitute.org/gsea/msigdb) were used in analysis.e7 Immunity 54, 1–19.e1–e8, June 8, 2021
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function from the packagemixOmics (Rohart et al., 2017). Unsupervised clustering of log2 transformed absolute cell counts, normal-
ized to the median of the corresponding control population, was conducted using the heatmap.2() function from the package gplots
(Warnes et al., 2020), with a Euclidean distance function applied to both rows and columns of the data matrix and hierarchical clus-
tering computed using the ward.D method. Partial least-squares discriminant analysis (PLS-DA) was conducted using the plsda()
function from the packagemixOmics (Rohart et al., 2017), a supervised method of sample discrimination whereby sample clustering
is informed by group membership (here patient clusters 1 and 2). The classification performance of the PLS-DA model was deter-
mined using the perf() function via 10 iterations of 5-fold cross-validation, with two components deemed sufficient to minimize the
balanced error rate of prediction. Variable selection on components 1 and 2 was conducted using the tune() function, with 13 cell
types selected as those most strongly contributing to discrimination of patient clusters. An AUROC curve showing the performance
of a predictive model based on these 13 cell types was generated using the auroc() function. To assess whether clinical severity was
reflected on a transcriptional level in an unsupervised fashion, K-means clustering was utilized on normalized whole blood RNASeq
gene expression counts. Heatmaps were created using the ComplexHeatmap package (Gu et al., 2016), with data scaled and
centered prior to visualization.
Cellular recovery rates over 60 days were calculated for each cell type in patients from groups C, D and E, split into those with
persistently elevated (> 10mg/L) or resolving CRP (falling below 10mg/L by final bleed), over 60 and 40 days respectively. Using a
12 day sliding windowwith single day increments, the ‘window of recovery’ for each given cell population was defined as the window
in which absolute cell counts for COVID-19 samples no longer differed from controls when assessed byWilcoxon test, and remained
as such for the subsequent 7 windows, and 80% of all windows remaining. Recovery rate was taken as the log2 normalized ratio of
test and control absolute counts for patient samples collected within the first timewindow (0-12 days), subtracted from the equivalent
value calculated within the window of recovery, divided by the upper day boundary of the recovery window.
The relationships between immunophenotyping and transcriptional data in the form of gene expression modules were assessed
using Pearson’s correlation (Hmisc package) and visualized with corrplot.Immunity 54, 1–19.e1–e8, June 8, 2021 e8
